Kisspeptin: complete guide to the KISS1 reproductive peptide

Kisspeptin is a neuropeptide. Encoded by the KISS1 gene on chromosome 1q32 ^[1], it sits upstream of nearly every signal that drives human reproduction. Without it, puberty doesn't happen.

That last point isn't rhetorical. In 2003, two independent groups identified loss-of-function mutations in the kisspeptin receptor as the cause of a rare form of congenital hypogonadotropic hypogonadism ^[2]. People who never went through puberty without exogenous hormone replacement. The finding rearranged the field. Until then, GnRH had been treated as the master regulator of the reproductive axis. As it turns out, GnRH neurons themselves are taking orders from somewhere further upstream, and kisspeptin is the loudest of those voices.

What makes kisspeptin different from other reproductive neuropeptides like GnRH or oxytocin is positional. GnRH executes the signal. Kisspeptin tells GnRH when and how often to fire. It's the timekeeper, not the messenger.

The KISS1 gene encodes a 145-amino-acid precursor protein ^[3]. That precursor gets cleaved into shorter bioactive fragments: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10 ^[4]. All four share an identical C-terminal ten-amino-acid sequence, and that conserved tail is what binds the receptor.

In practice, this means the isoforms are roughly equipotent at the receptor. Where they differ is pharmacokinetics. Kisspeptin-54 is the major circulating form and clears with a plasma half-life of about 28 minutes after IV infusion ^[5]. Kisspeptin-10 is shorter, slightly faster, and the workhorse of most rodent mechanistic studies. Kisspeptin-13 and -14 sit in between and get less research attention than they probably deserve.

The clinical implication: pick your fragment based on whether you want a longer endocrine signal (KP-54) or a sharper pharmacological probe (KP-10). Most of the human trial data uses KP-54.

Kisspeptin binds KISS1R, a Gq/11-coupled GPCR formerly known as GPR54 ^[6]. The downstream cascade is textbook for this receptor class. Phospholipase C hydrolyzes PIP₂ into IP₃ and DAG. IP₃ releases calcium from the endoplasmic reticulum, DAG activates protein kinase C, and ERK1/2 and p38 MAPK get phosphorylated downstream. β-arrestin recruitment modulates the ERK signal further.

On the membrane of the receiving GnRH neuron, the calcium rise does two things at once. It blocks inwardly rectifying potassium channels, and it activates TRPC channels. Both depolarize the cell. The neuron fires. GnRH gets released into the hypophyseal portal system, the pituitary responds with LH and FSH, and the gonads do what gonads do: testosterone in men, estradiol and progesterone in women, plus gamete production.

Two populations of kisspeptin neurons do most of this work. In the arcuate nucleus, kisspeptin neurons co-express neurokinin B and dynorphin (the so-called KNDy neurons), and they generate the pulses that drive baseline GnRH secretion. In the anteroventral periventricular nucleus, a second population mediates the estrogen-triggered LH surge that produces ovulation.

The KNDy framing matters for one specific reason. Fezolinetant, an NK3 receptor antagonist that targets this same circuit, received FDA approval in May 2023 for menopausal hot flashes ^[7]. That's the first regulatory validation of the broader KNDy pathway as a drug target, even though kisspeptin itself remains investigational.

The clearest evidence that kisspeptin drives puberty came from human genetics before it came from physiology. People with inactivating KISS1R mutations don't enter puberty. People with rare activating mutations enter it early, with central precocious puberty in some cases before age four.

The arc looks like this. Kisspeptin neurons are present and functional in infancy, then go largely silent through childhood. Sometime in late childhood, the arcuate kisspeptin system reactivates. GnRH pulse frequency climbs. The pituitary responds. Gonads wake up. Puberty unfolds over the next several years.

What flips the switch isn't fully settled. Leptin sensitivity, metabolic state, and a handful of inhibitory inputs that release the brake all show up in the data. Kisspeptin neurons express receptors for leptin, ghrelin, and insulin, which is how nutritional status couples to reproductive timing, and why severe undernutrition delays puberty while severe obesity sometimes accelerates it.

Pulsatility is the part that gets underappreciated outside reproductive endocrinology. GnRH isn't secreted continuously. It comes out in pulses, roughly every one to two hours in adult men, and at varying frequencies across the menstrual cycle in women. The pulse pattern carries information the pituitary reads: fast frequency favors LH, slower frequency favors FSH.

KNDy neurons in the arcuate generate that pulse rhythm. Kisspeptin is the output signal. Neurokinin B and dynorphin are the on-and-off switches that shape the timing. Knock out any of the three and pulsatility collapses.

This has a direct therapeutic consequence. Continuous kisspeptin infusion, the convenient way to dose a drug, desensitizes KISS1R and paradoxically suppresses the axis, the same way continuous GnRH agonist dosing chemically castrates prostate cancer patients. Any kisspeptin-based therapy has to either pulse the drug or use a molecule engineered around this problem.

Hypogonadotropic hypogonadism is the obvious indication. The defect sits upstream of GnRH; kisspeptin sits further upstream still. Restoring the signal at the right level should, in theory, restore the axis.

Early NIH-sponsored work registered as NCT00914823 tested kisspeptin administration in adults with HH ^[8], including protocols examining kisspeptin peptide fragments in combination with GnRH-related interventions. The mechanistic rationale: deliver a more physiological signal pattern than GnRH alone, with the goal of restoring more naturalistic testosterone or estradiol rhythms rather than the flat profiles produced by exogenous hormone replacement.

The early-phase results have been encouraging but narrow. Kisspeptin reliably elevates LH and FSH in HH patients who have intact GnRH neurons downstream. It does nothing in patients whose lesion sits at or below the GnRH neuron itself. Short answer: it works for the subset of HH where the wiring downstream of kisspeptin is intact, which is a meaningful but not universal slice of the patient population.

What the trials haven't yet shown is durable, real-world endocrine restoration over months or years. That's the gap.

PCOS sits at the other end of the axis problem. Where HH is too little signal, PCOS often involves too much: elevated LH, suppressed FSH, anovulation, hyperandrogenism.

A 2022 case-control study at Elena Doamna Hospital, published in Medicina, found PCOS patients had significantly elevated circulating kisspeptin levels alongside the expected LH elevation and FSH suppression. The interpretation, supported by multiple reviews in Frontiers in Endocrinology, is that KISS1 system over-activation drives at least some of the HPG axis hyperactivity that defines PCOS.

That's a mechanistic story, not a therapeutic one. If kisspeptin is part of what's wrong in PCOS, more kisspeptin probably isn't the treatment. The more interesting direction is the receptor agonist MVT-602, originally developed by Takeda as TAK-448 and later picked up by Myovant ^[9].

Two randomized placebo-controlled trials of MVT-602 enrolled healthy premenopausal women, PCOS patients, and women with hypothalamic amenorrhea. The pharmacology is notable. MVT-602 produced an LH peak similar in amplitude to native kisspeptin-54 but delayed, at 21.4 hours after dosing versus 4.7 hours for KP-54 (p=0.0002) ^[10]. LH area-under-the-curve was roughly four-fold higher (169.0 vs. 38.5 IU·h/L, p=0.0058) ^[11]. GnRH neuron firing duration extended from 55 to 115 minutes (p=0.0012) ^[12]. In hypothalamic amenorrhea patients, the LH response was advanced.

Translation: MVT-602 behaves like a longer-acting, more sustained kisspeptin signal. That's the profile suited to an injectable fertility drug.

In healthy eugonadal men, IV kisspeptin-54 reliably raises LH and FSH within minutes across a range of doses ^[13]. Testosterone follows on the expected delay. The Imperial College London series demonstrated significant gonadotropin stimulation at multiple dose levels, with the effect becoming robust at higher infusion rates.

The more provocative finding came from oocyte maturation work that doubled back into men's health. Native KP-54 has been investigated as an IVF trigger, including for women at high risk of ovarian hyperstimulation syndrome, a meaningful safety angle, since OHSS is one of the more dangerous complications of assisted reproduction. In men, the parallel question is whether kisspeptin can rescue spermatogenesis in HH or other gonadotropin-deficient states. Phase 2 work is ongoing. Nothing has reached a key endpoint.

This is where kisspeptin gets unexpectedly interesting, and where consumer interest tends to outrun the data.

In 2017, Comninos and colleagues published a randomized, placebo-controlled fMRI study in 29 healthy heterosexual men (JCI 89519) ^{[14] [15]}. Participants received either IV kisspeptin-54 at 1 nmol/kg/h or saline, viewed sexual and romantic images in the scanner, and the team measured brain activation patterns. Kisspeptin enhanced activity in regions associated with sexual arousal and pair-bonding. It reduced negative mood and sexual aversion ratings. LH climbed as expected, with a highly significant increase. Testosterone, oxytocin, and cortisol didn't move during the infusion window, meaning the brain effects weren't simply downstream of hormone change.

That last point is what made the paper notable. A direct central effect of kisspeptin on sexual processing, independent of the hormonal cascade.

A follow-up in 32 eugonadal men with hypoactive sexual desire disorder, using the same infusion protocol, found similar fMRI changes plus improvements in psychometric desire scores ^[16]. A separate proof-of-concept trial in women with HSDD (published in JAMA Network Open in 2022) reported statistically real modulation of brain activity in sexual and emotional pathways versus placebo, correlated with SADI score improvements.

Worth being careful here. These are early-phase studies. The endpoints are mostly fMRI BOLD signal and validated questionnaires, not durable behavioral change. Sample sizes are modest. Nobody has yet shown that a real-world dosing regimen produces clinically meaningful, sustained improvement in sexual function over months. The signal is interesting. The product doesn't exist.

A less-discussed application is using kisspeptin as a provocative diagnostic. The idea is straightforward: give a controlled dose, measure the LH and FSH response, and use the response curve to distinguish between hypothalamic, pituitary, and gonadal lesions.

A non-response to kisspeptin in someone with low gonadotropins suggests the problem sits at or downstream of the GnRH neuron. A strong response suggests an upstream lesion that exogenous kisspeptin can bypass. The same principle applies in evaluating delayed puberty in adolescents, where distinguishing constitutional delay from congenital hypogonadotropic hypogonadism is clinically difficult and consequential.

This is an off-label research use, not a fielded clinical assay. But the diagnostic logic is sound, and several academic centers are using kisspeptin challenge protocols within IND-authorized research.

The pharmaceutical landscape, as of mid-2026, is narrower than the science would suggest.

MVT-602 (TAK-448) is the most advanced kisspeptin receptor agonist in development. Originated at Takeda, licensed to Myovant, evaluated in two Phase 1/2 trials for female reproductive disorders including IVF protocols and hypothalamic amenorrhea. The pharmacokinetic profile, sustained LH stimulation from a single dose, is well-suited to fertility applications. No NDA or BLA has been submitted to FDA.

Native kisspeptin-54 continues in academic and NIH-sponsored trials, primarily at Imperial College London and U.S. Centers. Indications under investigation include IVF triggering, HSDD, HH, and pregnancy biomarker work. These remain investigational; none are on a near-term regulatory path as a product.

Fezolinetant, already approved, isn't a kisspeptin drug. It's an NK3 antagonist hitting the adjacent KNDy circuit. Its approval matters because it validated the regulatory pathway for KNDy-pathway drugs and built clinician familiarity with the underlying neuroscience.

The honest read: kisspeptin biology is unusually well-characterized for a peptide at this regulatory stage, and the absence of an approved product reflects commercial calculus and trial complexity more than mechanistic doubt.

In the published human infusion studies, kisspeptin-54 has been well-tolerated. Reported adverse events are mild and consistent with what you'd expect from an acute neuroendocrine stimulus.

The list, drawn from the trial literature: mild injection-site reactions with IV protocols, transient nausea in some participants, occasional headache, mild flushing tied to the acute LH and GnRH surge. No real cardiovascular events. At 1 nmol/kg/h over 75 minutes, cortisol, oxytocin, and testosterone don't move acutely ^[17].

TAK-683, a related synthetic analog, was well-tolerated across all tested doses in two randomized controlled trials in the Scott et al. series ^[18].

The FAERS database has some entries that look ominous on first read: hundreds of reports tagged with chronic kidney disease, hundreds more tagged drug ineffective. These are almost certainly confounded. There's no approved kisspeptin product to be reporting against, which means the signal is likely a mix of misattribution, dietary supplement reports, and noise.

Two theoretical safety concerns deserve more attention than they currently get. First, tachyphylaxis with continuous dosing, the receptor desensitization problem that turns kisspeptin from a stimulator into a suppressor if delivered the wrong way. Second, ovarian hyperstimulation in IVF contexts. Pregnancy safety in humans at therapeutic doses is also unknown, which is the standard situation for an investigational reproductive drug but worth naming directly.

Kisspeptin, across all native isoforms, is not FDA-approved for any indication. It's investigational. Clinical use occurs under IND authorization in research settings, and there's no FDA drug label.

It doesn't appear on the FDA's approved-for-compounding lists for either 503A or 503B pharmacies. A bulk substance qualifies under Section 503A only if it is on that list, carries a USP or NF monograph, or is a component of an approved drug — kisspeptin is none of the three. That places it outside the compounded-peptide channel some other research peptides have used to reach consumers, whatever a vendor's site implies.

Internationally, the picture is similar. No major regulator has approved a kisspeptin product for any indication. MVT-602 has cleared early-phase trials but has not advanced to a regulatory submission. The European Medicines Agency, UK MHRA, and other agencies treat kisspeptin as investigational.

What's legal right now: kisspeptin can be administered to research participants under appropriate regulatory authorization at institutions with active INDs. Outside that framework, it's not a fielded therapeutic.

A few things worth flagging plainly.

Long-term efficacy hasn't been established for any indication. The trials are mostly single-dose or short-duration. Whether repeated dosing maintains the LH response, induces tachyphylaxis, or produces tolerance is an open question for the native peptides.

The psychosexual data are intriguing but thin. fMRI activation patterns and questionnaire scores at 75 minutes post-infusion don't tell us what happens after weeks of treatment in people whose underlying sexual function complaints are heterogeneous in cause.

The PCOS story remains observational on the human side. We know kisspeptin levels are elevated in PCOS. We don't yet have a clean therapeutic that either suppresses kisspeptin signaling or restores normal pulsatility in a way that resolves the syndrome.

The IVF application is probably the closest to a defined regulatory path, with native KP-54 and MVT-602 both showing the kind of oocyte maturation profile that would justify a key trial. None has yet been run to that endpoint.

And the metabolic angle, including kisspeptin's effects on glucose-stimulated insulin secretion and the conflicting rodent data on isoform-dependent metabolic effects, is the area where the mechanism is most interesting and the human evidence thinnest. NCT04958109 enrolled 16 participants and reported that kisspeptin enhances insulin secretion in humans ^[19]. That's a starting point, not a conclusion.

For a peptide with this much mechanistic clarity and this many implicated indications, kisspeptin's clinical footprint is small. Whether that reflects a missing trial that hasn't been run yet, a commercial structure that doesn't favor short-half-life neuropeptides, or a series of harder-than-expected Phase 2 results that haven't been fully published: that's the question worth watching over the next few years.